X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (255) 255
animals (205) 205
index medicus (165) 165
male (134) 134
pyrans (126) 126
pyrans - pharmacology (122) 122
zanamivir (111) 111
female (107) 107
guanidines (104) 104
sialic acids - therapeutic use (91) 91
pharmacology & pharmacy (86) 86
antiviral agents - therapeutic use (85) 85
influenza, human - drug therapy (80) 80
adult (77) 77
mice (75) 75
pyrans - therapeutic use (60) 60
middle aged (59) 59
pyrans - chemistry (59) 59
neuraminidase - antagonists & inhibitors (58) 58
rats (58) 58
antiviral agents - adverse effects (56) 56
sialic acids - adverse effects (56) 56
oseltamivir (54) 54
aged (50) 50
influenza, human - prevention & control (50) 50
pyrans - adverse effects (50) 50
acetamides - therapeutic use (46) 46
efficacy (43) 43
dose-response relationship, drug (42) 42
chemistry, medicinal (41) 41
toxicology (41) 41
double-blind method (39) 39
influenza (38) 38
safety (38) 38
enzyme inhibitors - therapeutic use (37) 37
pyrans - administration & dosage (37) 37
iridoids (36) 36
adolescent (34) 34
analysis (34) 34
treatment outcome (34) 34
child (33) 33
antiviral agents - administration & dosage (31) 31
medicine, general & internal (31) 31
sialic acids - administration & dosage (29) 29
amantadine - therapeutic use (28) 28
pyrans - toxicity (28) 28
prevention (25) 25
structure-activity relationship (25) 25
in-vitro (24) 24
acetamides - adverse effects (23) 23
apoptosis (22) 22
cancer (22) 22
cell line, tumor (22) 22
molecular structure (22) 22
administration, oral (21) 21
oncology (21) 21
disease models, animal (20) 20
enzyme inhibitors - adverse effects (20) 20
medicine & public health (20) 20
administration, inhalation (19) 19
rimantadine - therapeutic use (19) 19
antineoplastic agents - pharmacology (18) 18
biochemistry & molecular biology (18) 18
cell survival - drug effects (18) 18
cytotoxicity (18) 18
neuraminidase inhibitor zanamivir (18) 18
proteins (18) 18
research (18) 18
resistance (18) 18
salinomycin (18) 18
care and treatment (17) 17
chemotherapy (17) 17
immunology (17) 17
influenza, human - virology (17) 17
pharmacology/toxicology (17) 17
pyrans - pharmacokinetics (17) 17
toxicity (17) 17
antiviral agents - pharmacology (16) 16
drug therapy (16) 16
expression (16) 16
influenza a virus (16) 16
pyrans - chemical synthesis (16) 16
article (15) 15
cell proliferation - drug effects (15) 15
chemistry, organic (15) 15
child, preschool (15) 15
clinical trials as topic (15) 15
double-blind (15) 15
drugs (15) 15
enzyme inhibitors - pharmacology (15) 15
health aspects (15) 15
internal medicine (15) 15
okadaic acid (15) 15
pyrans - analysis (15) 15
rabbits (15) 15
rats, wistar (15) 15
adults (14) 14
chickens (14) 14
diabetes mellitus, type 2 - drug therapy (14) 14
dosage and administration (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (398) 398
German (4) 4
Japanese (3) 3
Bulgarian (1) 1
Chinese (1) 1
Dutch (1) 1
Finnish (1) 1
French (1) 1
Italian (1) 1
Norwegian (1) 1
Russian (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e69086
Salinomycin is used as an antibiotic in animal husbandry. Its implication in cancer therapy has recently been proposed. Present study evaluated the toxic... 
CELLS | PROTEIN | ACID | LIPID-PEROXIDATION | RAT | SPERM | TESTIS | MULTIDISCIPLINARY SCIENCES | DNA-DAMAGE | BROILER-CHICKENS | CANCER | Sperm Count | Luteinizing Hormone - blood | Body Weight - drug effects | Epididymis - enzymology | Male | Testis - ultrastructure | Leydig Cells - drug effects | Leydig Cells - ultrastructure | Testis - drug effects | Sperm Motility - drug effects | Organ Size - drug effects | Animals | Testis - enzymology | Fertility - drug effects | Female | Anti-Bacterial Agents - adverse effects | Mice | Mice, Inbred BALB C | Pyrans - adverse effects | Testosterone - blood | Epididymis - drug effects | Epididymis - ultrastructure | Testosterone | Complications and side effects | Care and treatment | Pituitary hormones | Cytochrome P-450 | Luteinizing hormone | Dosage and administration | Superoxide | Glycoproteins | Cancer | Blood proteins | Cytochrome | Spermatozoa | Dehydrogenases | Spermatogenesis | Sperm | Lipid peroxidation | Reproductive organs | Hormones | Cancer therapies | Nuclei | Proteins | Toxicology | Mitochondria | Epididymis | Fertility | Leydig cells | Peroxidation | Tubules | Epithelium | Side effects | Chemotherapy | Infertility | Stem cells | Nuclei (cytology) | Endoplasmic reticulum | Oxidative stress | Toxicity | Lipids | Superoxide dismutase | Western blotting | Catalase | Rodents | Cell cycle | Glutathione | Reproductive systems | Cytochrome P450 | Organs | Lactate dehydrogenase | L-Lactate dehydrogenase | Acids | Antibiotics | Husbandry | Lactic acid | Reproductive system | Laboratory animals | Testes | Cytoplasm | Apoptosis
Journal Article
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 10/2017, Volume 33, Issue 10, pp. 1861 - 1868
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2017, Volume 19, Issue 11, pp. 1602 - 1609
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 09/2017, Volume 16, Issue 1, pp. 112 - 12
Background: Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in... 
Incretin | MK-3102 | Antihyperglycemic agent | Dipeptidyl peptidase-4 | METFORMIN | CARDIAC & CARDIOVASCULAR SYSTEMS | SULFONYLUREA | EFFICACY | SITAGLIPTIN | COMBINATION | TRIAL | ENDOCRINOLOGY & METABOLISM | OUTCOMES | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Risk Factors | Heterocyclic Compounds, 2-Ring - administration & dosage | Male | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Heterocyclic Compounds, 2-Ring - adverse effects | Diabetes Mellitus, Type 2 - diagnosis | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Female | Aged | Pyrans - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Pyrans - administration & dosage | Hypoglycemic Agents - adverse effects | Cardiovascular Diseases - diagnosis | Myocardial infarction | Heart | Drugs | Heart attacks | Clinical trials | Confidence intervals | Randomization | Failure analysis | Hemoglobin | Safety | Heart diseases | Drug dosages | Cerebral infarction | Stroke | Diabetes mellitus | Health risks | Data processing | Hazards | FDA approval | Patients | Insulin | Studies | Inhibitors | Infarction | Diabetes | Acute coronary syndromes
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 2016, Volume 44, Issue 9, pp. 1536 - 1542
Journal Article
Journal Article
Journal Article
Journal Article
Marine Drugs, ISSN 1660-3397, 04/2015, Volume 13, Issue 4, pp. 2306 - 2326
Our previous studies demonstrated that xyloketal B, a novel marine compound with a unique chemical structure, has strong antioxidant actions and can protect... 
eNOS | apoE-deficient mice | Atherosclerosis | Xyloketals | Endothelium | INDUCED HYPERTENSION | CELLS | OXIDATIVE STRESS | ACTIVATION | CHEMISTRY, MEDICINAL | FUNGUS XYLARIA SP | PHOSPHORYLATION | NITRIC-OXIDE SYNTHASE | OXIDIZED LDL | DIET-INDUCED OBESITY | MOUSE MODELS | Aorta - ultrastructure | Apolipoproteins E - deficiency | Human Umbilical Vein Endothelial Cells - metabolism | Humans | Lipid Metabolism, Inborn Errors - drug therapy | Diet, High-Fat - adverse effects | Endothelium, Vascular - drug effects | Male | Aorta - metabolism | Apolipoproteins E - metabolism | Proto-Oncogene Proteins c-akt - genetics | Endothelium, Vascular - ultrastructure | Lipid Metabolism, Inborn Errors - pathology | Protein Processing, Post-Translational - drug effects | Human Umbilical Vein Endothelial Cells - cytology | Pyrans - adverse effects | Aorta - physiopathology | Nitric Oxide Synthase Type III - metabolism | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Pyrans - pharmacology | Pyrans - therapeutic use | Human Umbilical Vein Endothelial Cells - drug effects | Specific Pathogen-Free Organisms | Lipid Metabolism, Inborn Errors - metabolism | Aorta - drug effects | Plaque, Atherosclerotic - prevention & control | Cells, Cultured | Endothelium, Vascular - physiopathology | Antioxidants - pharmacology | Nitric Oxide Synthase Type III - genetics | Cardiovascular Agents - pharmacology | Mice, Knockout | Plaque, Atherosclerotic - etiology | Cardiovascular Agents - therapeutic use | Lipid Metabolism, Inborn Errors - physiopathology | Antioxidants - therapeutic use | Animals | Endothelium, Vascular - metabolism | Antioxidants - adverse effects | Oxidative Stress - drug effects | Vasodilation - drug effects | Cardiovascular Agents - adverse effects | atherosclerosis | endothelium | xyloketals
Journal Article